TiPS, a venture in pharmacology

Trends in Pharmacological Sciences

Volumn 25, Issue 4, 2004, Pages 167-169

  Godfraind, Théophile ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOPAMINE RECEPTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; FATTY ACID; NITRIC OXIDE; PHOSPHOLIPASE C; PROSTAGLANDIN E;

BIOASSAY; CALCIUM TRANSPORT; CANCER; CHRONIC INFLAMMATION; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; EDITORIAL; ENDOTHELIUM; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VASODILATATION;

DRUG DESIGN; NOBEL PRIZE; PERIODICALS; PHARMACOLOGY;

EID: 1942421749     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.02.002     Document Type: Editorial

References (20)

1. Fredholm B.B., et al. The role of pharmacology in drug discovery. Nat. Rev. Drug Discov. 1:2002;237-238.
2. Horton E.W. Fifty years of prostaglandins. Trends Pharmacol. Sci. 1:1979;59-61.
3. Bonta I.L., Parnham M.J. Essential fatty acids or prostaglandins: therapeutic modulators of chronic inflammation? Trends Pharmacol. Sci. 1:1980;347-349.
4. Flower R.J. Eicosanoids: the nobel prize. Trends Pharmacol. Sci. 4:1983;1-2.
5. Bakhle Y.S. COX-2 inhibitors - panacea or paradox? Trends Pharmacol. Sci. 22:2001;646-647.
6. Black J.W., Shankley N.P. How does gastrin act to stimulate oxyntic cell secretion? Trends Pharmacol. Sci. 8:1987;486-490.
7. Taylor C.W., Merritt J.E. Receptor coupling to polyphosphoinositide turnover: a parallel with the adenylate cyclase system. Trends Pharmacol. Sci. 7:1986;238-242.
8. Fujino H., Regan J.W. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol. Sci. 24:2003;335-340.
9. Moncada S., et al. Endothelium-derived relaxing factor is identified as nitric oxide. Trends Pharmacol. Sci. 8:1987;365-368.
10. Radomski M.W., et al. Modulation of platelet aggregation by an arginine-nitric oxide pathway. Trends Pharmacol. Sci. 12:1991;87-88.
11. Clementi E., et al. Interactions between nitric oxide and sphingolipids and the potential consequences in physiology and pathology. Trends Pharmacol. Sci. 24:2003;518-523.
12. Calne D.B. Clinical relevance of dopamine receptor classification. Trends Pharmacol. Sci. 1:1980;412-414.
13. Nilsson J.L.G., Carlsson A. Dopamine-receptor agonist with apparent selectivity for autoreceptors: a new principle for antipsychotic action? Trends Pharmacol. Sci. 3:1982;322-325.
14. Bergson C., et al. Dopamine receptor-interacting proteins: the Ca2+ connection in dopamine signaling. Trends Pharmacol. Sci. 24:2003;486-492.
15. Suffness M., Douros J.D. Discovery of antitumor agents from natural sources. Trends Pharmacol. Sci. 2:1981;307-310.
16. Godfraind T., Kaba A. Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br. J. Pharmacol. 36:1969;549-560.
17. 2+ channels. Trends Pharmacol. Sci. 12:1991;349-354.
18. Godfraind T., et al. Tissue specificity of dihydropyridine-type calcium antagonists in human isolated tissues. Trends Pharmacol. Sci. 9:1988;37-39.
19. 2+ channel block. Trends Pharmacol. Sci. 23:2002;509-513.
20. Gerskowitch V.P., et al. Receptors on the agenda: a symposium to honour Sir James Black. Trends Pharmacol. Sci. 15:1994;355-361.